G1 Therapeutics, Inc. (GTHX) has 108 open-market insider trades by 20 insiders since 2017. The most active filer is Rajesh Malik.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Douglas Reed M.D. | 10% Owner | — | 3 | $44.2M | 2018-05-30 |
| MedImmune Ventures, Inc. | 10% Owner | — | 5 | $19.5M | 2017-12-15 |
| Fredric N. Eshelman | Dir10% Owner | — | 2 | $9.4M | 2017-11-13 |
| Mark A. Velleca | Dir | — | 21 | $8.7M | 2023-08-08 |
| Peter Kolchinsky | — | — | 1 | $6.0M | 2017-05-22 |
| Seth Rudnick | Dir | — | 8 | $3.6M | 2021-06-29 |
| Rajesh Malik | — | — | 24 | $3.6M | 2024-09-18 |
| John E. (Jack) Bailey Jr. | CEOPres | — | 7 | $1.8M | 2024-09-18 |
| Glenn P. Muir | Dir | — | 2 | $975K | 2024-09-18 |
| Terry L. Murdock | VP | — | 11 | $933K | 2024-09-18 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Andrew Perry | Chief Commercial Officer | Sell | $3K | 2024-07-05 |
| Rajesh Malik | Chief Medical Officer | Sell | $6K | 2024-07-05 |
| John E. (Jack) Bailey Jr. | President | Sell | $19K | 2024-07-05 |
| John W. V. Umstead | CFO | Sell | $1K | 2024-07-05 |
| Mark Avagliano | Chief Business Officer | Sell | $7K | 2024-07-05 |
| Monica R. Thomas | Chief Legal & People Officer | Sell | $25K |
Companies that share insiders with GTHX, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2024-05-23 |
| John E. (Jack) Bailey Jr. | CEO & President | Sell | $357K | 2024-05-13 |
| Rajesh Malik | Chief Medical Officer | Sell | $39K | 2024-05-13 |
| John W. V. Umstead | CFO | Sell | $20K | 2024-03-18 |
| Rajesh Malik | — | Sell | $132K | 2024-02-12 |
| John E. (Jack) Bailey Jr. | President | Sell | $36K | 2024-01-03 |
| Mark Avagliano | Chief Business Officer | Sell | $13K | 2024-01-03 |
| John W. V. Umstead | CFO | Sell | $2K | 2024-01-03 |
| Andrew Perry | Chief Commercial Officer | Sell | $8K | 2024-01-03 |
| Rajesh Malik | Chief Medical Officer | Sell | $12K | 2024-01-03 |